Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su gemcitabina/cisplatino più cemiplimab (REGN2810, Anti-PD-1) con o senza Fianlimab (REGN3767, Anti-LAG-3) in pazienti con cancro della vescica muscolo-invasivo localizzato (NeoSTOP-IT) (NeoSTOP-IT)

12 ottobre 2026 aggiornato da: Alexander Z. Wei, MD, Columbia University

Uno studio di fase 2, randomizzato, in aperto su gemcitabina/cisplatino più cemiplimab (REGN2810, Anti-PD-1) con o senza Fianlimab (REGN3767, Anti-LAG-3) per la conservazione degli organi in pazienti con cancro della vescica muscolo-invasivo localizzato (NeoSTOP-IT)

The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer?

Participants will be randomly selected (like the loss of a coin) to treatment with gemcitabine, cisplatin, cemiplimab, and fianlimab or gemcitabine, cisplatin, and cemiplimab.

Participants will:

  • Undergo transurethral resection of bladder tumor (TURBT) followed by the start of treatment, receive 4 cycles of treatment (21 day cycles)
  • After 4 cycles of treatment, patients will undergo repeat maximal TURBT with imaging
  • Participants with a complete response will continue maintenance cemiplimab or cemiplimab/fianlimab for 13 more cycles with imaging every 3 months
  • Participants without a complete clinical response will undergo cystectomy (bladder surgery).

Panoramica dello studio

Descrizione dettagliata

This is a phase 2, open-label, randomized trial with continuous toxicity monitoring to ensure safety using Bayesian toxicity monitoring, which will evaluate treatment with doublet platinum-based chemotherapy (gemcitabine and cisplatin) plus cemiplimab (REGN2810) with or without fianlimab (REGN3767) for localized muscle-invasive bladder cancer (MIBC). Participants will be randomized to 4 cycles of 3 weeks each (12 weeks total) with gemcitabine, cisplatin, and cemiplimab with or without fianlimab. Participants achieving a clinical complete response will continue 13 more cycles of immunotherapy (39 weeks total). The total duration of systemic treatment, including neoadjuvant therapy, will be 52 weeks.

In addition to the actual time on treatment, there will be time off treatment for recovery after neoadjuvant treatment and before adjuvant treatment. First, between the neoadjuvant phase and cystoscopy (with TURBT for residual disease), there will be up to 4 weeks off treatment. In between the cystoscopy/TURBT and start of adjuvant immunotherapy, there will be an additional up to 4 week interval for recovery. Participants will have regularly scheduled study visits at the clinical site on Day 1 and Day 8 of every three-week cycle in the neoadjuvant setting, where continuous assessment, including treatment response and safety assessments, will be performed. These will include laboratory tests, taking of vital signs, and physical examinations. In the adjuvant setting for participants who continue to maintenance immunotherapy, participants will have regularly scheduled study visits at the clinical site on Day 1 of every three-week cycle.

Response to treatment will be determined by three modalities. First, CT scans (chest, abdomen, and pelvis with and without contrast) to ensure no metastatic disease. For participants who are unable to get a CT scan w/ contrast due to renal function (or any other reason), an MRI with and without contrast may be used instead. Scans are required at baseline and every 3 months in the adjuvant setting for participants who continue on with maintenance immunotherapy. Second, all participants will undergo post-treatment cystoscopy every 3 months while on treatment. Third, all participants will undergo post-treatment urine cytology every 3 months while on treatment.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New York
      • New York, New York, Stati Uniti, 10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Willing and able to provide written informed consent for the trial.
  • Age ≥18 years of age on day of signing informed consent.
  • Life expectancy > 12 months.
  • Performance status of 0-1 using the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder defined as T2-T3, N0, M0 stage. Mixed histology is permitted if there is a urothelial component. Upper tract disease in not permitted.
  • Prior Bacillus Calmette-Guerin (BCG) or other intravesical treatment of non-muscle invasive bladder cancer is permitted if completed at least 6 weeks prior to initiating study treatment. Only one course (includes induction + maintenance) of BCG or intravesical therapy is permitted.
  • No metastatic disease based on cross-sectional imaging.
  • Considered cisplatin eligible based on protocol specified criteria.
  • Not received any adjuvant or neoadjuvant chemotherapy or immunotherapy.
  • Agree to pre- and post-treatment TURBT as well as surveillance with cystoscopies, cross-sectional imaging, and urine cytology unless medically contraindicated in the opinion of the treating physician, and discussed with the principal investigator

Exclusion Criteria:

  • Concurrent upper urinary tract (i.e., ureter, renal pelvis) invasive urothelial carcinoma. (NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post- treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no evidence of residual disease are eligible).
  • Received prior immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, anti-CTLA4, anti-LAG-3 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways ), as well as cellular vaccines, cellular therapies, or systemic oncolytic virus therapy.
  • Received bladder-directed radiation therapy previously for bladder cancer.
  • Received prior systemic chemotherapy for muscle-invasive bladder cancer.
  • Receiving any other investigational agents concurrently or within 4 weeks of start of treatment.
  • Had a solid organ or hematologic transplant.
  • Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose greater than 10mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Has a history of myocarditis.
  • Patients with another active second malignancy other than non-melanoma skin cancers.
  • Has a known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • History or current evidence of significant (Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.
  • Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection.
  • Is pregnant or is a breastfeeding woman.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group 1: Gemcitabine/Cisplatin/Cemiplimab
  • Gemcitabine 1000 mg/m^2 IV (days 1 and 8 of 21 day for 4 cycles)
  • Cisplatin 70 mg/m^2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose -cisplatin 35 m/m^2 IV (day 1 and 8 of 21 day cycle for 4 cycles)
  • Cemiplimab (REGN 2810) 350 mg IV every 3 weeks (17 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

Altri nomi:
  • REGN2810
Sperimentale: Group 2: Gemcitabine/Cisplatin/Cemiplimab/Fianlimab
  • Gemcitabine 1000 mg/m2 IV (days 1 and 8 of 21 day cycle for 4 cycles)
  • Cisplatin 70 mg/m2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose cisplatin 35 m/m2 IV (day 1 and 8 of 21 day cycle for 4 cycles )
  • Cemiplimab (REGN 2810) 350mg IV every 3 weeks (4 cycles)
  • Fianlimab (REGN3767) 1600mg IV every 3 weeks (4 cycles)

Gemcitabine 1000 mg/m^2 IV

Cisplatin 70 mg/m^2 IV or renally-dosed split-dose cisplatin 35 m/m^2 IV

Cemiplimab 350mg IV

Altri nomi:
  • REGN2810

Fianlimab 1600mg IV

Altri nomi:
  • REGN3767

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinical Complete Response
Lasso di tempo: 16 weeks

Rate of clinical complete response after 4 cycles of neoadjuvant chemoimmunotherapy. Complete clinical response will be defined as:

  • No high-grade malignancy on repeat TURBT
  • No malignant cells on urine cytology
  • No definitive evidence of invasive local or metastatic disease on cross-sectional imaging (CT chest, abdomen, and pelvis with contrast or, if renal dysfunction, MRI with contrast)

Cytoscopy and imaging should occur within 4 weeks of end of neoadjuvant therapy.

16 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Adverse Events
Lasso di tempo: 30 days after last dose of treatment, up to 56 weeks

Defined as the occurrence of any adverse event (AE) related to the investigational drugs at any point on treatment until 30 days after the last dose of treatment. AEs as evaluated per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

30 days after last dose of treatment, up to 56 weeks
Bladder-intact Survival
Lasso di tempo: Up to 5 years

Bladder-intact survival is defined as the time from start of treatment until cystectomy or death.

Up to 5 years
Recurrence-free Survival
Lasso di tempo: Up to 5 years

Recurrence-free survival is defined as the time from start of treatment until disease recurrence or death. Recurrence-survival will only be measured in patients who achieve a clinical complete response.

Up to 5 years
Overall Survival
Lasso di tempo: Up to 5 years

Overall survival is defined as the time from start of treatment until death.

Up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Alexander Z Wei, MD, Columbia University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 agosto 2025

Completamento primario (Effettivo)

5 gennaio 2026

Completamento dello studio (Effettivo)

5 gennaio 2026

Date di iscrizione allo studio

Primo inviato

23 agosto 2024

Primo inviato che soddisfa i criteri di controllo qualità

23 agosto 2024

Primo Inserito (Effettivo)

26 agosto 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi